Combination therapy for colorectal cancer that has spread to the liver
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of treatments for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It uses an oncolytic virus (which infects and kills cancer cells) along with radiation, chemotherapy, targeted therapy, and immunotherapy to try to shrink the liver tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have colorectal cancer that has spread to the liver and the liver tumors cannot be removed by surgery (or you choose not to have surgery).
- You need at least one liver tumor that can be injected with the study virus and is large enough (at least 10 mm) to be measured.
- Your liver function must be good (Child-Pugh score A or B), and you must be able to carry out daily activities (ECOG 0-1).
- You have not been treated before with immunotherapy drugs like PD-1 or PD-L1 inhibitors (for example, pembrolizumab or nivolumab).
- You cannot have had cancer that was found in the liver at the same time as the primary colorectal cancer (synchronous metastases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining focused radiation (SBRT) with immunotherapy for colorectal cancer that has spread to the liver or lungs. The goal is to see if this combination can shrink tumors and improve control of the cancer.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
Hear when a new CRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.